Protagenic Therapeutics Stock Price

0.23 (8.3%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Protagenic Therapeutics Inc PTIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.23 8.3% 3.00 19:59:57
Open Price Low Price High Price Close Price Prev Close
2.81 2.80 3.14 3.06 2.77
Bid Price Ask Price Spread News
3.00 3.07 0.07 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,722 1,924,670 $ 2.99 $ 5,758,699 4,326,009 1.842 - 4.89
Last Trade Time Type Quantity Stock Price Currency
19:59:57 formt 1,500 $ 3.00 USD

Protagenic Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 43.93M 14.64M 11.93M $ - $ - -0.26 -8.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 32.00k 30.20%

more financials information »

Protagenic Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PTIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.793.732.6213.093,887,5540.217.53%
1 Month2.984.192.162.854,279,0080.020.67%
3 Months2.754.891.8423.086,589,9150.259.09%
6 Months2.754.891.8423.086,589,9150.259.09%
1 Year2.754.891.8423.086,589,9150.259.09%
3 Years2.754.891.8423.086,589,9150.259.09%
5 Years2.754.891.8423.086,589,9150.259.09%

Protagenic Therapeutics Description

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.